Last update Aug. 7, 2019


Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Osteoinductive proteins that cause the formation of bone tissue at the implant site.
They belong to the family of transforming growth factors TGF-beta (TGF-β) (Gálvez 2004).
Indicated as a substitute for bone graft in fusion of lumbar vertebrae and in acute tibial fractures.
Surgical administration as a local implant.

Since the last update we have not found published data on its excretion in breastmilk.

Its high molecular weight and the fact that no systemic distribution has been detected after implantation and its half-life of a few minutes (EMA 2012, p5.2) make its excretion in breastmilk very unlikely.

Zero oral bioavailability is anticipated which would impede its transfer from breastmilk into infant plasma since, due to its protein nature, it degrades in the gastrointestinal tract, and is not absorbed.


We do not have alternatives for ジボテルミンアルファ.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


ジボテルミンアルファ belongs to this group or family:


Main tradenames from several countries containing ジボテルミンアルファ in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 30.000 daltons
(0.1) hours


  1. EMA-Medtronic. Dibotermina alfa (InductOs). Ficha técnica. 2012 Full text (in our servers)
  2. EMA-Medtronic. Dibotermin alfa (InductOs). Drug Summary. 2012 Full text (in our servers)
  3. EMA-Olympus. Eptotermina (Osigraft). Ficha técnica. 2011 Full text (in our servers)
  4. EMA-Olympus. Eptotermin (Osigraft). Drug Summary 2011 Full text (in our servers)
  5. FDA-Medtronic. Infuse Bone Graft. Drug Summary. 2004 Full text (in our servers)
  6. Gálvez-Gastélum FJ, Sandoval-Rodríguez AS, Armendáriz-Borunda J. El factor de crecimiento transformante β como blanco terapéutico. [Transforming growth factor-beta as a therapeutic target]. Salud Publica Mex. 2004 Jul-Aug;46(4):341-50. Review. Spanish. Abstract Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM